β-arrestin 2 modulates the activity of nuclear receptor RAR β2 through activation of ERK2 kinase

Oncogene

Volumn 25, Issue 2, 2006, Pages 218-229

  Piu, F ^a   Gauthier, N K ^a   Wang, F ^a  

^a ACADIA PHARMACEUTICALS INC   (United States)

Author keywords

Activation; Arrestin; MAP kinase; Nuclear receptor

Indexed keywords

BETA ARRESTIN 2; JANUS KINASE; LEUCINE; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE 2; NERVE GROWTH FACTOR; RETINOIC ACID RECEPTOR BETA; RETINOIC ACID RECEPTOR BETA 2; RETINOID X RECEPTOR; SERINE; SYNAPTOPHYSIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CANCER INHIBITION; CELL STRAIN; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; SITE DIRECTED MUTAGENESIS; TRANSCRIPTION INITIATION;

AMINO ACID SEQUENCE; ANIMALS; ARRESTINS; ENZYME ACTIVATION; GENE EXPRESSION REGULATION; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; LEUCINE; MICE; MITOGEN-ACTIVATED PROTEIN KINASE 1; MOLECULAR SEQUENCE DATA; MUTAGENESIS, SITE-DIRECTED; NERVE GROWTH FACTOR; NIH 3T3 CELLS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PC12 CELLS; RATS; RECEPTORS, RETINOIC ACID; SEQUENCE HOMOLOGY, AMINO ACID; SERINE; TRANSCRIPTION, GENETIC; TRANSFECTION;

ANIMALIA;

EID: 30544431968     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1209024     Document Type: Article

References (47)

1. Adam-Stitah S, Penna L, Chambon P, Rochette-Egly C. (1999). J Biol Chem 274: 18932-18941.
2. Ahuja HS, Szanto A, Nagy L, Davies PJ. (2003). J Biol Regul Homeost Agents 17: 29-45.
3. Andreatta-Van Leyen S, Hembree JR, Eckert RL. (1994). J Cell Physiol 160: 265-274.
4. Avruch J, Khokhlatchev A, Kyriakis JM, Luo Z, Tzivion G, Vavvas D et al. (2001). Recent Prog Horm Res 56: 127-155.
5. Barlic J, Andrews JD, Kelvin AA, Bosinger SE, DeVries ME, Xu L et al. (2000). Nat Immunol 1: 227-233.
6. Bennett BL, Sasaki DT, Murray BW, O'Leary EC, Sakata ST, Xu W et al. (2001). Proc Natl Acad Sci USA 98: 13681-13686.
7. Bourguet W, Vivat V, Wurtz JM, Chambon P, Gronemeyer H, Moras D. (2000). Mol Cell 5: 289-298.
8. Brauner-Osborne H, Brann MR. (1996). Eur J Pharmacol 295: 93-102.
9. Burstein ES, Hesterberg DJ, Gutkind JS, Brann MR, Currier EA, Messier TL. (1998). Oncogene 17: 1617-1623.
10. Corcoran J, Maden M. (1999). Nat Neurosci 2: 307-308.
11. Cosgaya JM, Aranda A. (2001). J Neurochem 76: 661-671.
12. Cuenda A, Rouse J, Doza YN, Meier R, Cohen P, Gallagher TF et al. (1995). FEBS Lett 364: 229-233.
13. Dalle S, Ricketts W, Imamura T, Vollenweider P, Olefsky JM. (2001). J Biol Chem 276: 15688-15695.
14. DeFea KA, Vaughn ZD, O'Bryan EM, Nishijima D, Dery O, Bunnett NW. (2000a). Proc Natl Acad Sci USA 97: 11086-11091.
15. DeFea KA, Zalevsky J, Thoma MS, Dery O, Mullins RD, Bunnett NW. (2000b). J Cell Biol 148: 1267-1281.
16. Delmotte MH, Tahayato A, Formstecher P, Lefebvre P. (1999). J Biol Chem 274: 38225-38231.
17. Demary K, Wong L, Liou JS, Faller DV, Spanjaard RA. (2001). Endocrinology 142: 2600-2605.
18. Egea PF, Mitschler A, Rochel N, Ruff M, Chambon P, Moras D. (2000). EMBO J 19: 2592-2601.
19. Favata MF, Horiuchi KY, Manos EJ, Daulerio AJ, Stradley DA, Feeser WS et al. (1998). J Biol Chem 273: 18623-18632.
20. Fox T, Coll JT, Xie X, Ford PJ, Germann UA, Porter MD et al. (1998). Protein Sci 7: 2249-2255.
21. Harish S, Ashok MS, Khanam T, Rangarajan PN. (2000). Biochem Biophys Res Commun 279: 853-857.
22. Holland PM, Cooper JA. (1999). Curr Biol 9: R329-31.
23. Ishaq M, Fan M, Natarajan V. (2000). J Immunol 165: 4217-4225.
24. Klaholz BP, Mitschler A, Moras D. (2000). J Mol Biol 302: 155-170.
25. Klaholz BP, Renaud JP, Mitschler A, Zusi C, Chambon P, Gronemeyer H et al. (1998). Nat Struct Biol 5: 199-202.
26. Kolch W. (2000). Biochem J 351(Part 2): 289-305.
27. Koutsilieris M, Reyes-Moreno C, Sourla A, Dimitriadou V, Choki I. (1997). Anticancer Res 17: 1461-1465.
28. Krupnick JG, Goodman Jr OB, Keen JH, Benovic JL. (1997). J Biol Chem 272: 15011-15016.
29. Kyriakis JM. (2000). Sci STKE 2000: E1.
30. Lee HY, Suh YA, Robinson MJ, Clifford JL, Hong WK, Woodgett JR et al. (2000). J Biol Chem 275: 32193-32199.
31. Lefebvre P, Martin PJ, Flajollet S, Dedieu S, Billaut X, Lefebvre B. (2005). Vitam Horm 70: 199-264.
32. Lin FT, Daaka Y, Lefkowitz RJ. (1998). J Biol Chem 273: 31640-31643.
33. Luttrell LM, Roudabush FL, Choy EW, Miller WE, Field ME, Pierce KL et al. (2001). Proc Natl Acad Sci USA 98: 2449-2454.
34. McDonald PH, Chow CW, Miller WE, Laporte SA, Field ME, Lin FT et al. (2000). Science 290: 1574-1577.
35. Miller LA, Cheng LZ, Wu R. (1993). Cancer Res 53: 2527-2533.
36. Miller WE, McDonald PH, Cai SF, Field ME, Davis RJ, Lefkowitz RJ. (2001). J Biol Chem 276: 27770-27777.
37. Ostrowski J, Roalsvig T, Hammer L, Marinier A, Starrett Jr JE, Yu KL et al. (1998). J Biol Chem 273: 3490-3495.
38. Piu F, Magnani M, Ader ME. (2002). Oncogene 21: 3579-3591.
39. Rakhit S, Pyne S, Pyne NJ. (2001). Mol Pharmacol 60: 63-70.
40. Renaud JP, Rochel N, Ruff M, Vivat V, Chambon P, Gronemeyer H et al. (1995). Nature 378: 681-689.
41. Rochette-Egly C, Oulad-Abdelghani M, Staub A, Pfister V, Scheuer I, Chambon P et al. (1995). Mol Endocrinol 9: 860-871.
42. Schmidt P, Holsboer F, Spengler D. (2001). Mol Endocrinol 15: 553-564.
43. Sharrocks AD, Yang SH, Galanis A. (2000). Trends Biochem Sci 25: 448-453.
44. Tahayato A, Lefebvre P, Formstecher P, Dautrevaux M. (1993). Mol Endocrinol 7: 1642-1653.
45. Vo HP, Lee MK, Crowe DL. (1998). Int J Oncol 13: 1127-1134.
46. Wang Z, Boudjelal M, Kang S, Voorhees JJ, Fisher GJ. (1999). Nat Med 5: 418-422
47. Wurtz JM, Bourguet W, Renaud JP, Vivat V, Chambon P, Moras D et al. (1996). Nat Struct Biol 3: 87-94.